Edit Symbol List
Enter up to 25 symbols separated by commas or spaces in the text box below. These symbols will be available during your session for use on applicable pages.
Don't know the stock symbol? Use the
Symbol Lookup tool.
Alphabetize the sort order of my symbols
Investing just got easier…
Sign up now to become a NASDAQ.com member and begin receiving instant notifications when key events occur that affect the stocks you follow.Access Now X
ETFs with MDVN as a Top 10 Holding*
|Weighting||ETF Name (Symbol)||100-Day Price Change (%)|
|2.88%||PowerShares Dynamic Biotech &Genome (PBE)||+6.41 (12.51%)|
Company Description (as filed with the SEC)
We are a biopharmaceutical company focused on the development and commercialization of medically innovative therapies to treat serious diseases for which there are limited treatment options. Through our collaboration with Astellas Pharma, Inc. or Astellas, we have one commercial product, XTANDI® (enzalutamide) capsules, or XTANDI. XTANDI has received marketing approval in the United States, Europe, and numerous other countries worldwide for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) and in Japan for the treatment of patients with castration-resistant prostate cancer (CRPC). Since its launch in the United States in September 2012, and subsequent launch in additional countries, XTANDI's worldwide net sales (as reported by Astellas) were approximately $1.6 billion through December 31, 2014. We and Astellas are also conducting investigational studies of enzalutamide in prostate cancer and in advanced breast cancer. ... More ...
Where does MDVN fit in the risk graph?
|Annual EPS Est:||$3.42|
|Quarterly EPS Est:||0.34|